A Phase 1 interventional study of Givinostat 10 mg/mL and Midazolam 1mg/ml IV in Drug-Drug Interaction and Heathy Volunteer, sponsored by Italfarmaco. Completed at 1 site in Portugal. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-06.
Sponsored by Italfarmaco · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary objective:
Secondary objective:
To assess the safety and tolerability of concomitant administration of givinostat plus midazolam and dabigatran etexilate.
This study was planned as a phase I, open-label, 3-part, fixed-sequence, nonrandomized study in healthy male and female subjects. The study evaluated the givinostat (ITF2357) potential drug-drug interaction (DDI) at level of CYP3A-mediated metabolism and P-glycoprotein (P-gp) transport with intravenous or oral midazolam and with oral dabigatran etexilate.
More precisely, the study aimed at assessing the potential (inhibitory or inducing) effect of givinostat on the PK of midazolam IV, on the PK of oral midazolam and on the PK of dabigatran etexilate.
The study lasted from Day 1 to Day 20. Subjects were confined from Day -1 to Day 20. On Days 6 and 17, single doses of 1 mg midazolam IV and 75 mg dabigatran etexilate, were administered 1 hour after the planned morning time of givinostat administration. On day 1, however, drugs were not administered 1h after gininostat.
On Days 7 and 18, a single oral dose of 2.5 mg midazolam oral solution was administered 1 hour after the planned morning time of givinostat administration.
On day 2, however, the drugs were not administered 1h after gininostat.
From Day 4 to Day 18, givinostat 50 mg as oral suspension was administered twice a day, in the morning and in the evening.
On Day 19, only the morning dose was administered.
The following assessments were performed:
The total duration of Part 1 for each subject was up to approximately 8 weeks from Screening to Follow-up visit, divided as follows:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria
A subject was considered eligible for the study if he/she fulfilled all the inclusion criteria:
Female subjects are eligible if they are of non- or agree to use a non-hormonal highly effective method from 28 days prior to Screening until at least 90 days after the last study drug administration. Nonchildbearing potential female is defined as:
A non-hormonal effective contraceptive method is defined as:
Exclusion Criteria
A subject was excluded from the study if he/she fulfilled any of the exclusion criteria:
At Screening
Any of the following abnormal laboratory test values:
Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Exclusion Criteria:
At Admission to Treatment Period
Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
For Part 1 subjects:
At Screening
Presence of a medical condition requiring anticoagulant treatment.
At Admission to Treatment Period
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Days 1, 6 and 17, single doses of midazolam 1 mg IV and dabigatran etexilate 75 mg were administered 1 hour after the planned (as per Day 4) morning time of givinostat administration. On Days 2, 7 and 18, a single oral dose of midazolam 2.5 mg oral solution was administered 1 hour after the planned (as per Day 4) morning time of givinostat administration. From Day 4 to Day 18, givinostat 50 mg as oral suspension was administered twice a day, in the morning and in the evening. On Day 19, only the morning dose was administered.
Drug: Givinostat 10 mg/mL · Drug: Midazolam 1mg/ml IV · Drug: Midazolam 2.5 mg oromucosal solution · Drug: Dabigatran etexilate 75 mg oral hard capsules
Drug page: Givinostat
10 mg/mL oral suspension. Givinostat 10 mg/ml oral suspension was administered once, in the morning, in Days 1, 2, 6, 7, 17 and 18), and twice a day (50 mg as oral suspension), in the morning and in the evening, from the Day 4 to Day 18. On Day 19, only the morning dose was administered.
Also known as: ITF2357
Drug page: Midazolam
Midazolam 1 mg/ml, solution for intravenous administration. Midazolam 1mg/ml IV, single dose, was administered on Days 1, 6 and 17, 1 hour after the planned morning time of givinostat administration. Midazolam IV were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
Also known as: Aurobindo®
Dose: 2.5 mg oromucosal solution. Midazolam 2.5 mg single oral solution was administered on Days 2, 7 and 18, 1 hour after the planned morning time of givinostat administration. Oral midazolam (and dabigatran etexilate) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose. Oral midazolam (and dabigatran etexilate) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before midazolam and dabigatran dosing until 2 hours postdose. Water was provided ad libitum at all other times. Midazolam (and dabigatran etexilate) were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
Also known as: Buccolam®
Dose: 75 mg; Dosage form: hard capsules On Days 1, 6 and 17, dabigatran etexilate 75 mg was administered (with midazolam 1mg IV) 1 hour after the planned morning time of givinostat administration. Dabigatran etexilate (and midazolam) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose Oral dabigatran etexilate (and oral midazolam) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before dabigatran (and midazolam) dosing until 2 hours postdose. Water was provided ad libitum at all other times. Dabigatran etexilate (and Midazolam) was administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
Also known as: Pradaxa
Cmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug
Maximum observed plasma concentration (Cmax) of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Administration of Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Cmax for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
Maximum observed plasma concentration (Cmax) of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected in K2-EDTA collection tubes at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17
Tmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug
tmax =Time of occurrence of Cmax. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Tmax for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
The time of occurrence of maximum observed concentration (tmax) of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17
t1/2 of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
T1/2 is the Apparent terminal elimination half-life, calculated as ln(2)/λz. t1/2 of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Administration of Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
t1/2 for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
Apparent terminal elimination half-life, calculated as ln(2)/λz. The t1/2 of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17
AUC0-t of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
AUC0-t =area under the curve from time zero to last sampling time with quantifiable concentrations. AUC0-t of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
AUC0-t for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
AUC0-t =area under the curve from time zero to last sampling time with quantifiable concentrations. AUC0-t of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17
AUC0-inf of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
AUC0-inf=Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
AUC0-inf for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
AUC0-inf = Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. AUC0-inf of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17
%AUCextrap of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
Area under the curve or AUC is a pharmacokinetic statistic used to describe the total exposure to a drug. More specifically, it is the time-averaged concentration of drug circulating in the body fluid analyzed (normally plasma, blood or serum). Standard calculation of AUC involves using non-compartmental techniques to calculate the AUC from time 0 to the last measurable concentration. This is called AUC0-t and represents the observed exposure to a drug. The total AUC or AUC0-∞ is the area under the curve from time 0 extrapolated to infinite time. %AUCextrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ∙(AUC0-∞ - AUC0-t) / AUC0-∞.
Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
%AUC0extrap (%) for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
Area under the curve (AUC) is a pharmacokinetic statistic used to describe the total exposure to a drug. More specifically, it is the time-averaged concentration of drug circulating in the body fluid analyzed. The total AUC (AUC0-∞) is the area under the curve from time 0 extrapolated to infinite time. * AUC0extrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ∙(AUC0-∞ - AUC0-t) / AUC0-∞. * AUC0extrap of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatra
Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17
λz of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
Apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non-zero concentrations. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
λz of Dabigatran (Total and Free), Following Single Doses of Givinostat
Apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non-zero concentrations. Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Number of Adverse Events by Severity (Mild, Moderate, Severe)
An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.
Time frame: Throughout the study and 10-14 days after the EoS (follow-up visit), i.e. up to date 30-34
Incidence of Patients With at Least One Adverse Events by Severity (Mild, Moderate, Severe)
An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.
Time frame: During the study and 10-14 days after the EoS (follow-up visit), i.e. up to day 30-34
Subjects were screened between Days -21 to -3 (both inclusive) of study part 1 to confirm that they met the subject selection criteria. Prior to any screening assessment, the Investigator (or an appropriate delegate) obtained informed consent from each subject in accordance with the procedures. 26 subjects were enrolled to study part 1. Please note that the overall figure n=104 is wrong; the system in fact automatically and inappropriately sums up the number of each IMP group.
| Milestone | All Study Participants (SAF and PK Population) |
|---|---|
| Started | 26 |
| Day 1 - midazolam (iv) 1 mg + dabigatran 75 mg | 26 |
| Day 2 - midazolam (oral) 2.5 mg | 26 |
| Days 4-5 - givinostat 50 mg b.i.d. | 26 |
| Day 6 - midazolam (iv) 1 mg + dabigatran 75 mg + givinostat 50 mg b.i.d. | 26 |
| Day 7 - midazolam (oral) 2.5 mg + givinostat 50 mg b.i.d. | 26 |
| Days 8-16 - givinostat 50 mg b.i.d. | 26 |
| Day 17 - midazolam (iv) 1 mg + dabigatran 75 mg + givinostat 50 mg b.i.d. | 26 |
| Day 18 - midazolam (oral) 2.5 mg + givinostat 50 mg b.i.d. | 26 |
| Day 19 - givinostat 50 mg | 26 |
| Completed | 26 |
| Not completed | 0 |
Maximum observed plasma concentration (Cmax) of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Administration of Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
| pg/mL | Midazolam IV Alone (Day 1) | Midazolam IV Co-administered With Givinostat (Day 6) | Midazolam IV Co-administered With Givinostat (Day 17) | Oral Midazolam Alone (Day 2) | Oral Midazolam Co-Administered With Givinostat (Day 7) | Oral Midazolam Co-Administered With Givinostat (Day 18) |
|---|---|---|---|---|---|---|
| midazolam | 50482.44 (42802.65 to 59540.16) | 53345.17 (46868.39 to 60716.97) | 46510.23 (38309.42 to 56466.57) | 12695.07 (11193.89 to 14397.57) | 15744.30 (13936.13 to 17787.09) | 17678.67 (15782.69 to 19802.43) |
| 1-hydroxymidazolam | 1426.41 (1269.56 to 1602.64) | 1306.05 (1146.91 to 1487.26) | 1335.02 (1115.15 to 1598.25) | 4451.49 (3756.90 to 5274.51) | 5229.06 (4445.58 to 6150.63) | 6303.67 (5046.18 to 7874.53) |
Maximum observed plasma concentration (Cmax) of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected in K2-EDTA collection tubes at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
| ng/mL | Dabigatran Etexilate Alone (Day 1) | Dabigatran Etexilate Co-Administered With Givinostat (Day 6) | Dabigatran Etexilate Co-Administered With Givinostat (Day 17) |
|---|---|---|---|
| total dabigatran | 69.44 (51.90 to 92.92) | 51.17 (39.62 to 66.08) | 45.35 (34.87 to 58.99) |
| free dabigatran | 60.19 (44.64 to 81.14) | 44.03 (34.49 to 56.21) | 37.41 (29.01 to 48.23) |
tmax =Time of occurrence of Cmax. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
| hours | Midazolam IV Alone (Day 1) | Midazolam IV Co-administered With Givinostat (Day 6) | Midazolam IV Co-administered With Givinostat (Day 17) | Oral Midazolam Alone (Day 2) | Oral Midazolam Co-Administered With Givinostat (Day 7) | Oral Midazolam Co-Administered With Givinostat (Day 18) |
|---|---|---|---|---|---|---|
| midazolam | 0.03 (0.03 to 0.03) | 0.03 (0.03 to 0.03) | 0.03 (0.03 to 0.25) | 0.55 (0.50 to 1.50) | 0.50 (0.50 to 1.50) | 0.50 (0.50 to 1.02) |
| 1-hydroxymidazolam | 0.50 (0.25 to 1.00) | 0.50 (0.25 to 2.00) | 0.51 (0.25 to 2.00) | 0.55 (0.50 to 1.50) | 0.50 (0.50 to 1.50) | 0.50 (0.50 to 1.02) |
The time of occurrence of maximum observed concentration (tmax) of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
| hours | Dabigatran Etexilate Alone (Day 1) | Dabigatran Etexilate Co-Administered With Givinostat (Day 6) | Dabigatran Etexilate Co-Administered With Givinostat (Day 17) |
|---|---|---|---|
| total dabigatran | 2.00 (1.50 to 4.00) | 2.00 (1.00 to 4.02) | 2.00 (1.00 to 4.00) |
| free dabigatran | 2.00 (1.00 to 4.00) | 2.00 (1.50 to 4.02) | 2.00 (1.50 to 6.00) |
T1/2 is the Apparent terminal elimination half-life, calculated as ln(2)/λz. t1/2 of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Administration of Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
| hours | Midazolam IV Alone (Day 1) | Midazolam IV Co-administered With Givinostat (Day 6) | Midazolam IV Co-administered With Givinostat (Day 17) | Oral Midazolam Alone (Day 2) | Oral Midazolam Co-Administered With Givinostat (Day 7) | Oral Midazolam Co-Administered With Givinostat (Day 18) |
|---|---|---|---|---|---|---|
| midazolam | 5.27 (4.60 to 6.04) | 5.22 (4.61 to 5.90) | 6.62 (5.83 to 7.51) | 5.48 (4.75 to 6.32) | 5.84 (5.08 to 6.70) | 6.73 (5.89 to 7.70) |
| 1-hydroxymidazolam | 4.02 (3.41 to 4.74) | 5.00 (4.20 to 5.95) | 5.74 (4.70 to 7.03) | 4.62 (3.63 to 5.89) | 6.09 (4.76 to 7.80) | 6.43 (5.16 to 8.01) |
Apparent terminal elimination half-life, calculated as ln(2)/λz. The t1/2 of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
| hours | Dabigatran Etexilate Alone (Day 1) | Dabigatran Etexilate Co-Administered With Givinostat (Day 6) | Dabigatran Etexilate Co-Administered With Givinostat (Day 17) |
|---|---|---|---|
| total dabigatran | 7.96 (7.52 to 8.42) | 8.01 (7.21 to 8.90) | 8.74 (8.17 to 9.36) |
| free dabigatran | 7.28 (6.73 to 7.89) | 7.03 (6.35 to 7.77) | 8.05 (7.30 to 8.88) |
AUC0-t =area under the curve from time zero to last sampling time with quantifiable concentrations. AUC0-t of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
| pg.h/mL | Midazolam IV Alone (Day 1) | Midazolam IV Co-administered With Givinostat (Day 6) | Midazolam IV Co-administered With Givinostat (Day 17) | Oral Midazolam Alone (Day 2) | Oral Midazolam Co-Administered With Givinostat (Day 7) | Oral Midazolam Co-Administered With Givinostat (Day 18) |
|---|---|---|---|---|---|---|
| Midazolam | 44094.42 (39998.55 to 48609.70) | 47333.50 (43297.80 to 51745.35) | 53692.16 (48609.52 to 59306.23) | 36483.20 (31064.96 to 42846.48) | 50134.44 (42444.64 to 59217.42) | 57559.53 (49279.79 to 67230.40) |
| 1-hydroxymidazolam | 5050.60 (4441.81 to 5742.83) | 5362.65 (4757.51 to 6044.76) | 6210.86 (5374.62 to 7177.22) | 10871.00 (9475.99 to 12471.38) | 14264.35 (12357.51 to 16465.42) | 17208.29 (14624.58 to 20248.46) |
AUC0-t =area under the curve from time zero to last sampling time with quantifiable concentrations. AUC0-t of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
| ng.h/mL | Dabigatran Etexilate Alone (Day 1) | Dabigatran Etexilate Co-Administered With Givinostat (Day 6) | Dabigatran Etexilate Co-Administered With Givinostat (Day 17) |
|---|---|---|---|
| total dabigatran | 552.25 (424.19 to 718.98) | 386.05 (299.12 to 498.25) | 386.23 (306.46 to 486.78) |
| free dabigatran | 460.16 (341.52 to 620.01) | 341.01 (268.24 to 433.52) | 332.71 (268.91 to 411.66) |
AUC0-inf=Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
| pg.h/mL | Midazolam IV Alone (Day 1) | Midazolam IV Co-administered With Givinostat (Day 6) | Midazolam IV Co-administered With Givinostat (Day 17) | Oral Midazolam Alone (Day 2) | Oral Midazolam Co-Administered With Givinostat (Day 7) | Oral Midazolam Co-Administered With Givinostat (Day 18) |
|---|---|---|---|---|---|---|
| Midazolam | 46054.19 (41834.50 to 50699.50) | 49532.66 (45406.00 to 54034.35) | 57112.86 (51342.91 to 63531.25) | 39037.54 (33096.57 to 46044.94) | 53379.48 (45107.58 to 63168.29) | 62904.03 (52906.81 to 74790.32) |
| 1-Hydroxymidazolam | 5720.13 (4981.56 to 6568.21) | 6404.39 (5615.24 to 7304.43) | 7821.70 (6736.26 to 9082.04) | 11914.16 (10292.86 to 13790.84) | 15895.61 (13769.86 to 18349.51) | 19199.79 (16300.75 to 22614.41) |
AUC0-inf = Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. AUC0-inf of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
| ng.h/mL | Dabigatran Etexilate Alone (Day 1) | Dabigatran Etexilate Co-Administered With Givinostat (Day 6) | Dabigatran Etexilate Co-Administered With Givinostat (Day 17) |
|---|---|---|---|
| total dabigatran | 563.09 (436.43 to 726.51) | 393.93 (306.01 to 507.11) | 396.25 (315.23 to 498.10) |
| free dabigatran | 467.79 (349.48 to 626.16) | 347.56 (273.95 to 440.95) | 347.73 (280.67 to 430.81) |
Area under the curve or AUC is a pharmacokinetic statistic used to describe the total exposure to a drug. More specifically, it is the time-averaged concentration of drug circulating in the body fluid analyzed (normally plasma, blood or serum). Standard calculation of AUC involves using non-compartmental techniques to calculate the AUC from time 0 to the last measurable concentration. This is called AUC0-t and represents the observed exposure to a drug. The total AUC or AUC0-∞ is the area under the curve from time 0 extrapolated to infinite time. %AUCextrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ∙(AUC0-∞ - AUC0-t) / AUC0-∞.
| Percentage of AUC0-inf | Midazolam IV Alone (Day 1) | Midazolam IV Co-administered With Givinostat (Day 6) | Midazolam IV Co-administered With Givinostat (Day 17) | Oral Midazolam Alone (Day 2) | Oral Midazolam Co-Administered With Givinostat (Day 7) | Oral Midazolam Co-Administered With Givinostat (Day 18) |
|---|---|---|---|---|---|---|
| Midazolam | 3.87 (3.23 to 4.63) | 3.96 (3.27 to 4.81) | 5.12 (4.07 to 6.43) | 5.02 (4.28 to 5.90) | 5.33 (4.31 to 6.59) | 5.79 (4.46 to 7.52) |
| 1-Hydroxymidazolam | 9.72 (7.55 to 12.52) | 13.20 (10.09 to 17.27) | 15.97 (12.14 to 21.02) | 6.95 (5.18 to 9.33) | 8.42 (6.62 to 10.70) | 8.80 (7.42 to 10.44) |
Area under the curve (AUC) is a pharmacokinetic statistic used to describe the total exposure to a drug. More specifically, it is the time-averaged concentration of drug circulating in the body fluid analyzed. The total AUC (AUC0-∞) is the area under the curve from time 0 extrapolated to infinite time. * AUC0extrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ∙(AUC0-∞ - AUC0-t) / AUC0-∞. * AUC0extrap of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatra
| Percentage of AUC0-inf | Dabigatran Etexilate Alone (Day 1) | Dabigatran Etexilate Co-Administered With Givinostat (Day 6) | Dabigatran Etexilate Co-Administered With Givinostat (Day 17) |
|---|---|---|---|
| total dabigatran | 1.37 (1.04 to 1.80) | 1.79 (1.50 to 2.15) | 2.23 (1.84 to 2.70) |
| free dabigatran | 1.27 (1.00 to 1.62) | 1.69 (1.39 to 2.05) | 2.02 (1.58 to 2.58) |
Apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non-zero concentrations. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.
| 1/h | Midazolam IV Alone (Day 1) | Midazolam IV Co-administered With Givinostat (Day 6) | Midazolam IV Co-administered With Givinostat (Day 17) | Oral Midazolam Alone (Day 2) | Oral Midazolam Co-Administered With Givinostat (Day 7) | Oral Midazolam Co-Administered With Givinostat (Day 18) |
|---|---|---|---|---|---|---|
| Midazolam | 0.131 (0.115 to 0.151) | 0.133 (0.118 to 0.150) | 0.105 (0.092 to 0.119) | 0.127 (0.110 to 0.146) | 0.119 (0.103 to 0.136) | 0.103 (0.090 to 0.118) |
| 1-Hydroxymidazolam | 0.172 (0.146 to 0.203) | 0.139 (0.116 to 0.165) | 0.121 (0.099 to 0.148) | 0.150 (0.118 to 0.191) | 0.114 (0.089 to 0.146) | 0.108 (0.087 to 0.134) |
Apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non-zero concentrations. Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.
| 1/h | Dabigatran Etexilate Alone (Day 1) | Dabigatran Etexilate Co-Administered With Givinostat (Day 6) | Dabigatran Etexilate Co-Administered With Givinostat (Day 17) |
|---|---|---|---|
| Total Dabigatran | 0.087 (0.082 to 0.092) | 0.087 (0.078 to 0.096) | 0.079 (0.074 to 0.085) |
| Free dabigatran | 0.095 (0.088 to 0.103) | 0.099 (0.089 to 0.109) | 0.086 (0.078 to 0.095) |
An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.
| number of TEAE | Midazolam | Dabigatran | Givinostat | Total |
|---|---|---|---|---|
| AE mild severity | 28 | 25 | 74 | 127 |
| AE moderate severity | 0 | 0 | 2 | 2 |
| AE severe | 0 | 0 | 0 | 0 |
An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.
| Participants | Midazolam | Dabigatran | Givinostat | Total |
|---|---|---|---|---|
| AE mild severity | 26 | 26 | 26 | 26 |
| AE moderate severity | 2 | 2 | 2 | 2 |
Collected over Throughout the study and 10-14 days after the End of Study (safety follow-up visit), i.e. up to day 30-34, all TEAEs, considered related or not related to IMPs, were collected.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Midazolam | 0/26 (0%) | 0/26 (0%) | 26/26 (100%) |
| Dabigatran | 0/26 (0%) | 0/26 (0%) | 26/26 (100%) |
| Givinostat | 0/26 (0%) | 0/26 (0%) | 26/26 (100%) |
| Event | Midazolam | Dabigatran | Givinostat |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 19/26 | 19/26 | 19/26 |
| SomnolenceNervous system disorders | 17/26 | 17/26 | 17/26 |
| Dry skinSkin and subcutaneous tissue disorders | 10/26 | 10/26 | 9/26 |
| DyspepsiaGastrointestinal disorders | 7/26 | 7/26 | 7/26 |
| Faeces softGastrointestinal disorders | 5/26 | 5/26 | 4/26 |
| NauseaGastrointestinal disorders | 5/26 | 5/26 | 5/26 |
| Blood creatine phosphokinase increasedInvestigations | 3/26 | 3/26 | 3/26 |
| DysgeusiaNervous system disorders | 3/26 | 3/26 | 3/26 |
| Eye pruritusEye disorders | 2/26 | 2/26 | 2/26 |
| Abdominal discomfortGastrointestinal disorders | 2/26 | 2/26 | 2/26 |
Pharmacokinetic Analysis Population:Twenty-six (26) subjects were enrolled in Part 1 of the study and provided evaluable pharmacokinetic data for at least one IMP, without deviations affecting pharmacokinetic interpretation.
| Age, Categorical(Participants) | Number of Subjects Enrolled |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 26 |
| >=65 years | 0 |
| Age, Continuous(years) | Number of Subjects Enrolled |
|---|---|
| Mean | 34 ± 8.2 |
| Sex: Female, Male(Participants) | Number of Subjects Enrolled |
|---|---|
| Female | 7 |
| Male | 19 |
| Race (NIH/OMB)(Participants) | Number of Subjects Enrolled |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 22 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Number of Subjects Enrolled |
|---|---|
| Portugal | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2022 to primary completion in May 2022, 1 month.
Results were first posted in Jan 2025, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Givinostat · Midazolam